Last reviewed · How we verify
EBA-175 RII-NG Malaria Vaccine
EBA-175 RII-NG Malaria Vaccine is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 1 development.
At a glance
| Generic name | EBA-175 RII-NG Malaria Vaccine |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly (PHASE1)
- EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EBA-175 RII-NG Malaria Vaccine CI brief — competitive landscape report
- EBA-175 RII-NG Malaria Vaccine updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about EBA-175 RII-NG Malaria Vaccine
What is EBA-175 RII-NG Malaria Vaccine?
EBA-175 RII-NG Malaria Vaccine is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID).
Who makes EBA-175 RII-NG Malaria Vaccine?
EBA-175 RII-NG Malaria Vaccine is developed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).
What development phase is EBA-175 RII-NG Malaria Vaccine in?
EBA-175 RII-NG Malaria Vaccine is in Phase 1.